Bronchothiol

Quick links to important sections

Bronchothiol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronchothiol

Property Description
Active ingredient Carbocisteine
Form Oral solution or syrup
Pharmacological class Mucolytic (Expectorant)
Primary Use Relief of thick mucus in respiratory affections
Status Available as both OTC and Prescription (Rx)

Bronchothiol is an established international brand name for a medicine containing the active ingredient carbocisteine, which is classified as a mucolytic agent. It is widely used to manage respiratory conditions characterized by the overproduction of thick, persistent mucus (sputum) in the airways, such as acute bronchitis and exacerbations of chronic conditions like Chronic Obstructive Pulmonary Disease (COPD).

As a mucolytic, carbocisteine works by altering the chemical structure of the mucus, specifically by modifying its glycoproteins. This action reduces the mucus's viscosity (thickness and stickiness), making it easier for a patient to clear the substance from the lungs through coughing—a process known as expectoration.

Differentiation: Bronchothiol is distinctive as its active ingredient, carbocisteine, is clinically recognized not only for thinning mucus but also for having additional antioxidant and anti-inflammatory properties that may benefit patients with chronic airway diseases. The medicine is commonly formulated as a palatable oral solution or syrup, available in different strengths for both adults and children over the age of two. Its widespread use is primarily established in the European and Asian markets, as carbocisteine is not currently approved for use by the U.S. Food and Drug Administration (FDA).

Regulatory References

  1. Expectoration Definition (NIH)
  2. Carbocisteine Mechanism (NIH)
  3. Carbocisteine UNII (FDA/SRS)

What side effects are possible with Bronchothiol?

Possible side effects and safety information

The documented safety profile of carbocisteine is based on regulatory data, with adverse reactions categorized by System Organ Class and reported frequency. Gastrointestinal issues and skin reactions are the most frequently observed effects, though many are classified as rare or of unknown frequency.

Documented Adverse Reactions and Frequencies

Adverse effects listed in regulatory documents include gastrointestinal disorders such as diarrhoea, nausea, vomiting, and epigastric discomfort. Reactions affecting the skin and immune system, such as skin rash, pruritus (itching), urticaria, and angioedema, are also reported. Other system-organ classes involved include Nervous System disorders (headache, dizziness) and Cardiac disorders (palpitations), typically reported as rare.

Serious Adverse Reactions

Regulatory safety information specifically highlights the potential for rare but serious adverse reactions. These include gastrointestinal bleeding and severe skin reactions known as dermatitis bullous, which encompasses conditions such as Stevens-Johnson syndrome and erythema multiforme. Anaphylactic reactions (severe allergic response) are also documented. Official instructions specify that treatment should be stopped immediately if severe skin reactions or gastrointestinal bleeding occurs.

Safety Considerations for Specific Populations

Use of this medicine is contraindicated in children younger than two years of age, and in individuals with active peptic ulceration. Caution is advised for older adults and those with a history of gastroduodenal ulcers, especially if they are taking concurrent medications that increase the risk of bleeding. Use is not recommended for women who are pregnant or breast-feeding.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation identifies the gastrointestinal system as the primary site of effects in an overdose scenario involving carbocisteine (Bronchothiol). The most likely clinical manifestations of overdosage are gastrointestinal disturbances, which include specific symptoms such as gastralgia (stomach pain), nausea, vomiting, and diarrhea. Overdosage is categorized by regulatory bodies as an intensification of these adverse effects that can result from accidental massive ingestion.

Emergency Management and Actions

Management of overdosage relies on procedural guidance detailed in official prescribing information. Supportive therapy must be instituted, and symptomatic treatment is recommended to manage the documented gastrointestinal effects. For cases involving massive ingestion, the procedure of gastric lavage may be considered. Following any such intervention, the official guidance mandates that the patient should be managed by observation.

No specific antidote is listed in the regulatory text. While the official label mandates the institution of supportive treatment, seeking urgent medical attention is necessary if massive ingestion has occurred or if symptoms of gastrointestinal disturbance are severe and persistent, as the required management involves professional procedural steps and structured observation.

Therapeutic Uses of Bronchothiol

Bronchothiol is commonly used to help with symptoms related to excessive and viscous phlegm (sputum) in the respiratory tract. Its application is relevant across domains where additional symptomatic support is needed to manage mucus hypersecretion. Its use is indicated as an adjunctive therapy for respiratory tract disorders characterized by excessive, viscous mucus, including chronic obstructive airways disease.


The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, such as acute bronchitis and flare-ups of chronic conditions like COPD and bronchiectasis. It is also considered relevant for localized secretory issues, including otitis media with effusion. The medication is considered relevant for easing the difficulty of clearing mucus, which contributes to easing the overall symptom load associated with retained secretions.

“This symptomatic management assists patients during difficult episodes by supporting the handling of distress and strain associated with persistent, thick phlegm.”


Quick Fact: Relief for Viscous Secretions

The application may assist with maintaining functional stability by supporting better airway secretion clearance over time, which is relevant for managing symptoms that become more disruptive during flare-ups.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bronchothiol?

Eligibility to use Bronchothiol (carbocisteine) is strictly defined by regulatory guidance and is based on age, physiological status, and underlying medical conditions.

Who Cannot Use Bronchothiol (Contraindications)

Individuals with the following conditions or characteristics must not use this medicine, as specified in regulatory labeling:

  • Active Peptic Ulceration: This includes current gastric or duodenal ulcers.
  • Hypersensitivity: Known allergy to carbocisteine or any of the medicine's excipients.
  • Children Under Two Years Old: Use is formally contraindicated in this age group.

Eligibility by Age and Status

Population Group Regulatory Status
Adults and Adolescents Approved for use.
Children Approved from two years of age and above.
Pregnancy and Breastfeeding Not Recommended due to limited or insufficient data, as noted in official prescribing information.

Restrictions and Special Precautions

Use of Bronchothiol requires caution for the elderly and those with a history of gastroduodenal ulcers. Patients with a history of ulcers must immediately discontinue the medicine if any signs of gastrointestinal bleeding occur.

What should I know about interactions with other medicines?

The official regulatory profile for Bronchothiol (carbocisteine) is defined by a limited number of documented pharmacodynamic and substance interactions. No formal metabolic (CYP-mediated) or specific drug transporter interactions requiring dosing adjustments are documented in prescribing information.

Restrictions on Co-administration

Certain combinations are classified as irrational or carry restrictions based on opposing pharmacodynamic effects. Co-administration is generally restricted with Antitussives (cough suppressants) because the suppression of the cough reflex directly counteracts the mucolytic goal of clearing secretions. Similarly, substances that actively dry up bronchial secretions, such as Anticholinergics or Atropine-like agents, should not be co-administered, as their action opposes the therapeutic effect.


Cautionary and Distributional Interactions

A specific cautionary warning is issued for the concomitant use of Bronchothiol with medicinal products that increase the risk of gastrointestinal bleeding. This includes agents such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Oral Corticosteroids, as an additive risk for gastrointestinal hemorrhage is officially noted. This heightened risk is a particular consideration for elderly patients. Additionally, regulatory documents note that carbocisteine may influence the local distribution of certain antibiotics, such as Amoxicillin or Erythromycin, by enhancing their penetration into bronchial secretions. Finally, the ethanol content in some oral solution formulations requires careful consideration, representing a documented product substance interaction.

Mechanism of Action

How Bronchothiol Works: Mechanism of Action

Carbocisteine exhibits mucolytic activity and influences the production of bronchial secretions at a molecular level.

Breakdown of Mucus Structure

Its core mechanism is the ability to reduce the viscosity and elasticity of existing mucus. It achieves this by acting within molecular cascades to disrupt disulfide bonds that cross-link the large mucin glycoproteins, which results in altered rheological properties of the secretion, influencing the mechanics of mucociliary clearance from the airways.


Regulation of Mucus Quality and Production

Carbocisteine influences the cellular production pathways of new secretions. It modulates the activity of mucus-secreting cells to support the synthesis of lower-viscosity glycoproteins (sialomucins) over the stickier ones (fucomucins). This action contributes to a modified state within targeted pathways, altering the rheological properties of newly formed secretions.


Modulation of Airway Inflammatory Cascades

Secondary effects concern the drug's influence on cellular signaling. It engages mechanisms that can modulate oxidative stress and local inflammatory pathways within the bronchial lining, which is associated with altered activity of mucus-secreting cells.

Dosage and Administration Information

Bronchothiol, which contains the active ingredient carbocisteine, is administered exclusively via the oral route. It is supplied in various forms, including capsules (e.g., 375 mg) and oral liquids such as syrup (e.g., 250 mg/5 ml).

The administration protocol for adults and the elderly follows a defined two-phase system. Treatment initiates with a higher initial daily dose of 2250 mg of carbocisteine, taken in divided doses, typically three times per day. Once a satisfactory response is observed, the dose is reduced to a maintenance daily dose of 1500 mg in divided doses.

For the proper intake of the medicine, administration is flexible and may occur with or without food. If a liquid formulation is used, the dose is accurately measured using the dedicated measuring device supplied with the package, as household spoons are unsuitable for pharmaceutical dosing.

Specific rules apply to the pediatric population: the medicine is contraindicated for use in children under two years of age. For children aged two and older, the dose is weight-based, typically calculated as 20 mg per kilogram of body weight daily in divided doses. The duration of use varies, spanning from a short course for acute symptoms to a long-term management plan for chronic conditions. If a dose is missed, the standard practice is to skip the forgotten dose and never take two doses at once to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bronchothiol (Carbocisteine)


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research has explored the use of Bronchothiol (carbocisteine) in patients with Chronic Obstructive Pulmonary Disease (COPD) through long-term, controlled clinical trials. These studies focused on adults with chronic obstructive airways disease and research examined primary outcomes reflecting daily functioning, such as the frequency and severity of COPD flare-ups (exacerbations).

Studies conducted during periods of increased symptom activity reported patterns related to exacerbation frequency in certain adult populations. Some trials also described patterns related to patient-reported outcomes, where patients reported changes in their symptom intensity over the study period. Evidence remains limited regarding long-term outcomes on disease progression itself beyond one year of observation. Certainty remains low for a universal pattern of findings.


Evidence for Management of Acute Respiratory Symptoms

Research has also explored the use of Bronchothiol in conditions characterized by fluctuating or episodic manifestations, such as short-term bronchitis. These investigations often involved short-term Randomized Controlled Trials (RCTs) over an acute treatment period. The studies explored specific outcomes related to physical discomfort, focusing on objective measures of sputum thickness (viscosity) and subjective descriptions of perceived ease of clearing phlegm (expectoration).

Trials reported measurements related to mucus viscosity following the study period. Some studies described a pattern of how patients reported the perceived ease of sputum clearance compared to control groups. However, the existing studies provide limited insight into any sustained outcome after the acute episode resolves because follow-up durations were limited.


What the Research Landscape Shows About Uncertainty

The research landscape for Bronchothiol highlights that evidence quality varies across studies, with a mix of high-quality RCTs and smaller trials. While some studies described patterns related to patient-reported outcomes in chronic conditions, findings were mixed concerning the consistency of all outcomes across all studied groups. Data are still emerging on long-term outcomes beyond one year, and the evidence is limited for specific patient groups, making personalized predictions difficult. Studies help show what has been observed so far, but the evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Bronchothiol (FAQ)


Q: Is Bronchothiol an antibiotic or just for coughing?

A: Bronchothiol is officially classified as a mucolytic agent. This means it is not an antibiotic. Its main role is to alter the thickness and stickiness of mucus, making it easier for a person to clear phlegm from the airways through coughing.


Q: How quickly should I expect Bronchothiol to start working?

A: Official information indicates that the medicine’s pharmacological action begins immediately upon intake. Patient reports and official information suggest symptom improvement may become noticeable after regular use.


Q: What is the main difference between Bronchothiol and other cough medicines?

A: Bronchothiol's active ingredient, carbocisteine, is a mucolytic, which specifically acts by changing the chemical structure of mucus to thin it out. The co-administration of cough suppressants is generally restricted in regulatory guidance because they counteract its action.


Q: Can Bronchothiol be taken with cold and flu medicine?

A: Official guidance advises caution when taking Bronchothiol with certain cold and flu medicines. It is restricted with cough suppressants, which counteract its action. Additionally, regulatory documents warn about using it with medicines that increase the risk of stomach bleeding, which includes NSAIDs (like ibuprofen), often found in multi-symptom cold relief products.


Q: Are there any common foods or drinks that should be avoided when using Bronchothiol?

A: Official prescribing information states that there are generally no known food interactions with the active ingredient. Patients can usually eat and drink as they normally would while taking this medicine.


Q: Does Bronchothiol make you drowsy or affect driving?

A: Official guidance usually states that the medicine does not typically impair the ability to drive or ride a bike. However, some documented side effects, such as dizziness or nervous system disorders, have been reported rarely. As with many medicines, individuals are advised to note how they respond to the medicine before driving or operating machinery.


Q: Is it normal to feel a bit nauseous after taking Bronchothiol?

A: Nausea is listed in regulatory documents as a common side effect of carbocisteine. Gastrointestinal issues like this, vomiting, or diarrhea are among the more frequently reported adverse reactions. Official documents note that dietary measures may help manage this common effect.


Q: What should I do if I accidentally used more Bronchothiol than described?

A: Regulatory guidance advises contacting a doctor or hospital casualty department immediately if more than the prescribed amount is accidentally used. An overdose is most likely to result in an upset stomach or other gastrointestinal disturbances.


Q: Is it okay to use Bronchothiol long-term?

A: The duration of use is determined by the condition being managed. For some chronic conditions, such as COPD, regulatory documents describe its use as part of a long-term management plan. The appropriateness of long-term use is determined by a healthcare professional.


Q: Do any official sources suggest Bronchothiol interacts with blood thinners?

A: Official sources issue a cautionary warning regarding the concomitant use of Bronchothiol with medicines that increase the risk of gastrointestinal bleeding. This risk applies to agents such as NSAIDs and antiplatelet medicines, which are a type of blood thinner.


Q: What is the typical timeframe someone uses Bronchothiol?

A: The typical timeframe is highly variable and depends on the specific illness being treated. For short-term issues like acute bronchitis, use is generally a short course. For chronic, ongoing conditions like COPD, regulatory evidence indicates it may be used as part of a long-term management plan.


Q: Is Bronchothiol sold under any other names internationally?

A: Yes, the medicine contains the active ingredient carbocisteine. While 'Bronchothiol' is an established brand name, the product may be sold under various other local brand names in different regions (for example, Mucodyne is a common UK brand name for carbocisteine).


Q: Does Bronchothiol help with shortness of breath?

A: The official stated action of the medicine is focused on making thick, sticky mucus easier to clear through coughing (expectoration). While effectively clearing mucus may lead to a feeling of easier breathing, regulatory claims are centered on mucus clearance, not directly on treating the symptom of shortness of breath (dyspnea).


Q: Is Bronchothiol available without a prescription in some places?

A: Yes, regulatory statuses vary internationally. The medicine is generally available under both Prescription Only Medicine (Rx) status and Over-the-Counter (OTC) status, depending on the country, the product's strength, and the specific indication for which it is being sold.


Q: Can people with asthma use Bronchothiol?

A: Official indications primarily focus on conditions like COPD and chronic bronchitis that involve thick mucus. The medicine is not listed as a formal contraindication for use in asthma in regulatory documents. However, as with any respiratory condition, individual use of the medicine is determined by a healthcare professional.


Q: Is it possible to use Bronchothiol with herbal supplements?

A: Official regulatory safety bodies note that caution is advised when considering use with herbal remedies. There is often not enough information to confirm safety because complementary or herbal remedies are not tested in the same way as regulated medicines.


Q: Why do some people say Bronchothiol makes their cough feel 'looser'?

A: This patient perception is directly linked to the drug's intended action. The medicine works by breaking down the cross-links in the mucus structure, which is designed to make the phlegm less sticky and thick. This change in consistency allows the person to clear the substance from their airways with a perceived 'looser' or easier cough.


Q: Does using Bronchothiol require any special monitoring?

A: Routine clinical monitoring is not generally required for this medicine. However, official guidance requires patients with a history of gastroduodenal ulcers to self-monitor and immediately discontinue the medicine if signs of gastrointestinal bleeding occur.


Q: Is Bronchothiol used for conditions other than respiratory issues?

A: While the main use is for respiratory conditions with thick mucus, the medicine’s official indications in some regions include use for non-respiratory issues. Specifically, some regulatory monographs list its use for drainage in chronic sinusitis and drainage in otitis media with effusion (middle ear infection).

How should Bronchothiol be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing Bronchothiol (carbocisteine oral solution) to maintain its stability.

Storage Requirement Conditions Mandated by Labeling
Temperature Do not store above 25 C to 30 C. Do not refrigerate or freeze.
Protection Keep the medicine in the original container and outer carton to protect it from light.
Child Safety Must be kept out of the sight and reach of children.

The oral solution has a limited in-use shelf-life. Once the bottle is opened, the product must be discarded after a specific period, typically one to three months, depending on the formulation's labeling.

Disposal of unused or expired Bronchothiol must follow local requirements and must not be thrown into household waste or wastewater. Patients are instructed to return the product to a pharmacist for appropriate pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronchothiol found in:

A-Z Index: